Background: The recent development of tissue microarray (TMA) technology allows highthroughput protein expression profiling of cancer tissues by immunohistochemistry. We attempted to clarify the derivation of undifferentiated-type gastric carcinoma with tubular component by using TMA. Methods: We constructed a TMA system composed of six paraffin blocks in which 274 samples of formalin-fixed gastric carcinoma tissue from 274 patients were embedded. Using this system, we performed immunohistochemical stains for five tumor suppressor and tumor-related proteins, i.e. p53, p16, hMLH1, c-erbB-2 and carcinoembryonic antigen (CEA). The 274 gastric carcinomas were histopathologically divided into the following three groups according to the degree of differentiation: differentiated-type (D-type), undifferentiated-type with tubular component (UT-type) and pure undifferentiated-type (UP-type). Immunohistochemical results were then compared with histological types. Results: The percentages of abnormal expression of each protein in D-type, UT-type and UP-type carcinomas were as follows: 27% (38/143), 17% (17/98) and 15% (5/33) for p53; 27% (39/143), 19% (19/98) and 18% (6/33) for p16; 38% (54/143), 44% (43/98) and 24% (8/33) for hMLH1; 15% (22/143), 5% (5/98) and 0% (0/33) for c-erbB-2; and 22% (31/143), 35% (34/98) and 70% (23/33) for CEA. UP-type carcinomas exhibited the lowest frequencies of abnormal expression for p53, p16, hMLH1 and c-erbB-2, but the highest frequencies for CEA. UT-type carcinomas generally showed intermediate frequencies between those of D-type and UP-type carcinomas. Differences between D-type and UP-type for c-erbB-2 (P < 0.05) and CEA (P < 0.001) were significant, as were differences between D-type and UT-type for c-erbB-2 (P < 0.05) and CEA (P < 0.05), and differences between UT-type and UP-type for hMLH1 (P < 0.05) and CEA (P < 0.001). Conclusions: These findings reveal that gastric carcinomas have distinct expression profiles for tumor suppressor and tumor-related proteins depending on histological types, and support the hypothesis that UT-type carcinomas are derived not only from D-type but also from UP-type carcinomas. We also found significant differences between abnormal protein expression and other clinicopathological parameters such as gender, age and status of tumor and nodes.
INTRODUCTION
Recent progress in molecular biology has shown that the phenotypic diversity of tumors is associated with corresponding diversity in gene expression (1) (2) (3) . Techniques involving cDNA microarrays have been applied to study gene expression patterns in different tumor types, providing new insights into development and classification of these cancers. Recently, Kononen et al. (4) developed tissue microarray (TMA) techniques that simultaneously produce comprehensive protein expression profiles for numerous tumors. TMA appears to be particularly useful for immunohistochemical characterization of tumors (5) (6) (7) . This technology has been used extensively and is the subject of multiple reviews (6) (7) (8) (9) (10) .
Gastric cancers are classified either as differentiated-type (D-type) carcinoma, which forms tubular or papillary structures roughly corresponding with intestinal type, or undifferentiated-type (U-type) carcinoma, in which such structures are inconspicuous (roughly corresponding with diffuse type) (11, 12) . D-type carcinomas are thought to evolve from intestinal metaplastic mucosa and U-type tumors from native gastric mucosa (13) . Although a significant proportion of D-type carcinomas are thought to progress to U-type (13) , there have been few studies which focused on this transformation. For the present study, we subdivided undifferentiated carcinomas into U-type carcinoma with tubular component (UT-type) and pure undifferentiated carcinoma (UP-type) based upon the presence or absence of tubular components. Because different genetic pathways have been proposed for D-type and U-type carcinomas (13, 14) , they should exhibit different protein expression profiles. Five tumor suppressor and tumor-related proteins, p53, p16, hMLH1, c-erbB-2 and carcinoembryonic antigen (CEA), which frequently show abnormal expression in gastric cancer were selected for this study. We then used TMA to create expression profiles for those proteins in gastric carcinomas according to the histological types.
MATERIALS AND METHODS

CLINICAL SAMPLES
A total of 274 surgically resected gastric cancers were examined. The patients were 188 males and 86 females (mean age, 68 years; range, 32-88 years). The tumors consisted of 64 early (depth of invasion limited to the mucosa or submucosa) and 210 advanced (depth of invasion reached the muscularis propria) carcinomas. Nodal metastasis was present in 144 patients, and distant metastasis in 7 patients. All specimens were fixed in 10% formalin and embedded in paraffin. The tumors were classified according to tumor-node-metastasis (TNM) staging (8) at the Department of Pathology, Yamagata University School of Medicine, between 1996 and 2001. Histologically, gastric cancers were classified as either of D-type, which forms tubular or papillary structures, or U-type carcinoma, in which such structures are inconspicuous. U-type carcinomas were subdivided into U-type carcinoma with tubular component (UT-type) and pure undifferentiated carcinoma (UP-type) which included poorly differentiated adenocarcinoma without tubular component and signet-ring cell carcinoma.
TMA CONSTRUCTIONS
A map of receiver block was prepared with coordinates for each sample to correctly identify the tumor. Under a microscope, areas of interest that were non-necrotic and rich in tumoral glands were marked with an indelible pen on the whole hematoxylin and eosin stained (H&E) section of each donor block. TMAs were constructed using a manual tissue arrayer (KIN-1; Azumaya, Tokyo, Japan). The system consists of thin-walled stainless-steel needles with an inner diameter of $2 mm and a stiletto for transferring and emptying needle contents. Specimens are retrieved from selected regions of donor tissue and precisely arrayed in a new recipient block.
One core per donor block for each case sampling 2 mm in diameter and using 0.8 mm edge-to-edge spacing was arrayed in six recipient blocks. TMA blocks were incubated at 60 C for 30 min.
IMMUNOHISTOCHEMISTRY
Serial 4 mm thick tissue sections were cut from array blocks, with initial sections H&E stained to verify histology. Immunostaining for p53 (Pab1801; Novocastra, Newcastle, UK) (1 : 40 dilution), p16 (F-12; Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1 : 100 dilution), hMLH1 (G168-728; PharMingen, San Diego, CA, USA) (1 : 50 dilution), c-erbB-2 (DakoCytomation, Glostrup, Denmark) (1 : 100 dilution) and CEA (1B2; IBL, Tokyo, Japan) (1 : 100 dilution) was performed using a standard labeled streptavidin-biotin system (Nichirei, Tokyo, Japan). Positivity was >50% nuclear staining for p53, p16 and hMLH1, membranous staining for c-erbB-2 and cytoplasmic staining for CEA. Immunohistochemical reactivity was independently evaluated by two investigators (T.H., G.T.), with consensus reached after discussion.
STATISTICAL ANALYSIS
Correlation between expression of each tumor suppressor and tumor-related protein and tumor differentiation, as well as correlation with other clinicopathological parameters, was compared by Fisher's exact probability test and chi-square for independence test. A P-value <0.05 was considered to be statistically significant. (TABLE 1) UP-type carcinomas exhibited the lowest frequencies of abnormal expression for p53, p16, hMLH1 and c-erbB-2, but the highest frequency for CEA. UT-type carcinomas generally showed intermediate frequencies between those of D-type and UP-type. Differences between D-type and UP-type for c-erbB-2 (P < 0.05) and CEA (P < 0.001), differences between D-type and UT-type for c-erbB-2 (P < 0.05) and CEA (P < 0.05), and differences between UT-type and UP-type for hMLH1 (P < 0.05) and CEA (P < 0.001) were significant. An example of immunohistochemistry is shown in Fig. 1 . (TABLE 2) Overexpression of p53 was observed more frequently in older patients (P < 0.05), with early tumor status (P < 0.05) and with negative nodes (P < 0.05). Loss or reduction of p16 was associated with negative nodes (P < 0.01). Expression of hMLH1 was more frequently reduced or lost in older patients (P < 0.01) and with advanced tumor status (P < 0.05). Expression of c-erbB-2 was more common with early tumor status (P < 0.05). Cytoplasmic CEA expression was frequent in tumors from female (P < 0.05) and younger (P < 0.05) patients, and with positive nodes (P < 0.05).
RESULTS
EXPRESSION OF TUMOR SUPPRESSOR AND TUMOR-RELATED PROTEINS IN DIFFERENTIATED AND UNDIFFERENTIATED GASTRIC CANCERS
CORRELATION BETWEEN TUMOR SUPPRESSOR AND TUMOR-RELATED PROTEIN EXPRESSION AND OTHER CLINICOPATHOLOGICAL PARAMETERS
DISCUSSION
TMA allows simultaneous analysis of large numbers of specimens, resulting in high-throughput data acquisition. Because all tissue specimens analysed are arrayed on one identical TMA, antigen retrieval, reagent concentrations, incubation times with primary antibodies, temperatures and wash conditions are identical for each core (15,16), resulting in an unprecedented level of standardization over and above that available with standard histopathological techniques. In addition, because small quantities of reagent and fewer personnel are required, this method is extremely efficient and cost-effective. Histopathological benefits include minimal destruction of original tissue blocks, which are often considered vital resources, and the presence of internal positive and negative controls on the TMA. Because such small specimens are sampled, many rare cell lines can be assessed with ease (17) . One potential limitation of TMA is that very small cores may not be representative of whole tumors, particularly in heterogeneous cancers such as prostate adenocarcinoma. However, excellent correlation has been reported between data obtained from TMA and conventional blocks in a variety of tumor types such as breast, prostate, bladder and human fibroblastic tumors (15) . Furthermore, in the most extensive study investigating validation in prostate cancer, Rubin et al. (18) found that only 3-4 optimal cores of 0.6 mm diameter were necessary to predict outcome after radical prostatectomy for local prostate cancer. Similarly, other groups have found that sampling with optimal cores was sufficient to accurately detect clinicopathological correlations (15, 19) . Interestingly, these studies have shown that increasing the number of cores to compensate for heterogeneity and inevitable losses confers only a slightly higher rate of validity while producing the significant disadvantages of additional labor in arraying a larger number of arrays and lack of efficiency in processing tissues. In the present study, we used a single core after microscopic identification of representative histopathology with reference to a serial H&E stained section for each patient. Our large core size, 2 mm in diameter, allowed easy recognition of cell types with positive and negative immunoreactivity.
In the present study, we have demonstrated that UP-type carcinomas exhibited the lowest frequencies of abnormal expression for p53, p16, hMLH1 and c-erbB-2, but the highest frequencies for CEA. UT-type carcinomas generally showed intermediate frequencies between those of D-type and UP-type carcinomas. Differences between D-type and UT-type for cerbB-2 and CEA were statistically significant, as were differences between UT-type and UP-type for hMLH1 and CEA. Thus, UT-type carcinoma have aspects of both D-type and UPtype at protein level suggesting that UT-type carcinomas might 
582
Tissue microarray analysis of gastric cancer be derived not only from D-type but also from UP-type carcinomas. Recently, Peng et al. (20) have shown that poorly differentiated gastric carcinoma with a tubular component, which corresponds to UT-type in the present study, usually develops from tubular adenocarcinomas (D-type) and sometimes from signet-ring cell carcinoma (UP-type) by comparative genomic hybridization (CGH) analyses. p53 expression was most frequent in D-type (26.6%) and infrequent (15.2%) in UP-type tumors, although this difference was not significant. The relatively low rate of p53 immunoreactivity (21%, 60/274) might be owing to the cut-off value of 50%; however, comparison of single-strand conformation polymorphism/sequencing and immunohistochemistry of p53 alterations revealed the propriety of using a cut point of >50%. Infrequent p53 mutation (3.8%, 1/26) in undifferentiated gastric carcinoma has been noted (21) . In addition, p53 overexpression was seen more frequently in tumors with early tumor status (Tis and T1) than with advanced status (T2a-T4), a finding consistent with a previous report that found p53 mutation was more frequent in early carcinomas . In a D-type carcinoma, immunoreactivity is prominent for p53 (B), p16 (C), hMLH1 (D) and c-erbB-2 (E), but absent for CEA (F). In a UP-type carcinoma, it is prominent for p16 (I) and CEA (L), but absent for p53 (H), hMLH1 (J) and c-erbB-2 (K). 
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Tissue microarray analysis of gastric cancer than in advanced ones (22) . The significantly lower rate of immunoreactivity against p53 in younger patients was also consistent with a previous report on p53 mutations (23) . Correlation between p53 expression and nodal status is controversial (23, 24) . We found less frequent p53 expression in node-positive cases, probably because early carcinomas commonly expressed p53. Reduced expression of p16 owing to promoter hypermethylation results in higher cyclin D1-dependent protein kinase activity and aberrant phosphorylation of Rb that play roles in the pathogenesis of gastric cancer (25) (26) (27) . No significant differences between p16 expression and histological differentiation were observed, probably because p16 was commonly affected by promoter hypermethylation in both differentiated and undifferentiated gastric cancers (28) . In the present study, reduced p16 protein expression was more frequent in nodenegative tumors, although no significant association was noted in previous studies (25, 26, 29) .
Since inactivation of hMLH1 in association with DNA methylation was first reported in colorectal cancer (30) , similar epigenetic alterations have been described in gastric cancer (13, 31) . DNA methylation of hMLH1 promoter region CpG islands is tightly associated with loss of hMLH1 expression in gastric cancers that exhibit microsatellite instability (MSI) (31, 32) . Loss of hMLH1 protein was less frequent in UPtype carcinoma, which is in agreement with the finding that MSI-H (high frequency MSI) is absent in this type of carcinoma (21) and loss of hMLH1 expression owing to promoter hypermethylation plays a critical role in D-type carcinoma (32, 33) . The frequencies of loss of hMLH1 expression increased with patient age and advanced tumor stage, both of which are consistent with previous reports (28, 34) .
Overexpression of c-erbB-2 has been detected in 10-50% of gastric carcinomas and is correlated with a poor prognosis (35) (36) (37) . The great majority of gastric carcinomas with c-erbB-2 overexpression are histologically intestinal type (35) (36) (37) , which corresponds with D-type carcinoma in our study. The correlation between c-erbB-2 expression and status of tumor and nodes has been controversial (35) (36) (37) , although c-erbB-2 overexpression was more frequent in early carcinomas in the present study.
CEA is one of the most useful tumor markers of adenocarcinoma (38) . All signet-ring cell carcinomas are intensively positive for CEA (38) . In the current study, cytoplasmic CEA expression was significantly associated with undifferentiated histology, especially UP-type, which includes signet-ring cell carcinoma. In addition, CEA expression was associated with female gender, younger age and positive nodes, confirming the significance of this protein expression as a biological marker.
Thus, gastric carcinomas show distinct expression profiles of tumor suppressor and tumor-related proteins depending on tumor differentiation. This supports the hypothesis that UTtype carcinomas are derived not only from D-type but also from UP-type carcinomas. Furthermore, abnormal protein expression has a characteristic association with clinicopathological parameters. TMA is a useful technique for rapid identification of protein expression profiles using minimal samples from archived tissues.
